Oral semaglutide 25 mg was associated with the same weight loss efficacy in women with obesity regardless of menopausal stage, and patients reported improvements in physical function, respectively
Approval is based on results from the phase 3 OASIS 4 clinical trial
The move signals a major expansion in access to next-generation weight-loss therapies
Operating profit fell 1% in Danish kroner to DKK 127.7 billion but rose 6% at constant exchange rates
Wegovy pill showed a mean weight loss of 16.6% in the OASIS 4 trial
Wegovy achieved significant weight loss with one in three study participants losing 20% or more body weight
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
